Aducanumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Identifiers | |
| CAS Number | 1384260-65-4 |
| ATC code | none |
| Chemical data | |
| Molecular mass | 145.9 kg/mol |
Aducanumab is the given USAN and INN name for a biopharmaceutical, the human monoclonal antibody and drug candidate BIIB037 designed for treatment of Alzheimer's disease (AD).[1] It is being developed by Biogen Idec, which licensed the drug candidate from Neurimmune, its discoverer.[2] The antibody targets aggregated forms of beta amyloid.[3] Interim results from the second Phase 1 study of the drug were reported at the 12th International Conference on Alzheimer’s and Parkinsons’s Diseases and Related Neurological Disorders (AD/PD 2015), in Nice, France, in March 2015.[1][4]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />- ↑ 1.0 1.1 Cynthia Fox for Drug Discovery and Development. April 28, 2015 The Story of Biogen's Alzheimer's Drug, Aducanumab
- ↑ Rebecca Zacks for Xconomy. November 20th, 2007 Biogen Inks $380 Million Deal With Swiss Company
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Matthew Herper for Forbes. March 20, 2015 Biogen Drug Could Inspire New Hope For Alzheimer's Treatments
Categories:
- Pages with reference errors
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoclonal antibodies
